Clinical Trials
8 trialsNCT03155620 2026-06-01
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04284774 2026-05-27
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02210858 2018-06-04
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00454480 2013-08-26
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00047190 2013-06-04
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005967 2013-02-11
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00040105 2012-08-01
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00022451 2012-03-15
Tipifarnib in Treating Young Patients With Refractory Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Completed